Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 20, 2021 - Issue 5
Submit an article Journal homepage
2,832
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies

Mina Tsurumia Rare Disease Medical, Sanofi Genzyme Medical, Sanofi K.K., Tokyo, JapanCorrespondence[email protected]
View further author information
,
Shinya Suzukia Rare Disease Medical, Sanofi Genzyme Medical, Sanofi K.K., Tokyo, JapanView further author information
,
Jiro Hokugob Post-Authorization Regulatory Studies, Medical Affairs, Sanofi K.K., Tokyo, JapanView further author information
&
Kazuo Uedaa Rare Disease Medical, Sanofi Genzyme Medical, Sanofi K.K., Tokyo, JapanORCID Iconhttps://orcid.org/0000-0003-3369-2771View further author information
ORCID Icon
Pages 589-601 | Received 28 Jan 2021, Accepted 12 Feb 2021, Published online: 10 Mar 2021

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.